Maximus (NYSE:MMS) Sets New 1-Year Low – Time to Sell?
by Sarita Garza · The Markets DailyShares of Maximus, Inc. (NYSE:MMS – Get Free Report) hit a new 52-week low on Thursday . The stock traded as low as $62.51 and last traded at $62.6150, with a volume of 718750 shares trading hands. The stock had previously closed at $64.10.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on the stock. Wall Street Zen cut shares of Maximus from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Zacks Research upgraded shares of Maximus from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 30th. Finally, Weiss Ratings cut shares of Maximus from a “buy (b)” rating to a “hold (c+)” rating in a research note on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy”.
Maximus Price Performance
The company has a market cap of $3.40 billion, a price-to-earnings ratio of 9.49 and a beta of 0.63. The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 0.88. The business has a 50-day moving average price of $75.75 and a 200 day moving average price of $83.45.
Maximus (NYSE:MMS – Get Free Report) last issued its earnings results on Thursday, February 5th. The health services provider reported $1.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.84 by $0.01. Maximus had a return on equity of 25.30% and a net margin of 6.92%.The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.37 billion. During the same period in the previous year, the firm posted $1.61 EPS. The company’s quarterly revenue was down 4.1% on a year-over-year basis. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS. As a group, research analysts expect that Maximus, Inc. will post 6.15 earnings per share for the current fiscal year.
Maximus Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were issued a dividend of $0.33 per share. This represents a $1.32 annualized dividend and a yield of 2.1%. The ex-dividend date was Friday, February 13th. This is a boost from Maximus’s previous quarterly dividend of $0.30. Maximus’s dividend payout ratio is presently 20.09%.
Insider Buying and Selling at Maximus
In other news, CEO Bruce Caswell bought 3,175 shares of the firm’s stock in a transaction on Tuesday, February 10th. The stock was bought at an average cost of $78.45 per share, for a total transaction of $249,078.75. Following the completion of the acquisition, the chief executive officer directly owned 328,013 shares in the company, valued at $25,732,619.85. This represents a 0.98% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Jan Madsen sold 742 shares of Maximus stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $72.25, for a total transaction of $53,609.50. Following the completion of the transaction, the director directly owned 20,795 shares in the company, valued at approximately $1,502,438.75. This trade represents a 3.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.80% of the company’s stock.
Institutional Trading of Maximus
Several large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada increased its holdings in shares of Maximus by 146.2% in the 1st quarter. Royal Bank of Canada now owns 19,732 shares of the health services provider’s stock valued at $1,345,000 after purchasing an additional 11,716 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Maximus by 0.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,476 shares of the health services provider’s stock worth $2,351,000 after buying an additional 221 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Maximus by 7.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 180,690 shares of the health services provider’s stock worth $12,321,000 after buying an additional 11,754 shares in the last quarter. Jane Street Group LLC boosted its stake in shares of Maximus by 941.2% during the 1st quarter. Jane Street Group LLC now owns 98,273 shares of the health services provider’s stock valued at $6,701,000 after buying an additional 88,835 shares during the period. Finally, Sivia Capital Partners LLC acquired a new stake in shares of Maximus during the 2nd quarter valued at $204,000. 97.21% of the stock is owned by institutional investors and hedge funds.
Maximus Company Profile
Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.